StockData
Erasca, Inc. logo

Erasca, Inc. (ERAS) stock

ERASNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$13.89−1.22 (-8.07%)

Close on Nov 17, 2026Market cap $4.86BP/E –Yield 0.00%

Erasca r&d expenses

Research and development expenses are spending on new products and technology.

Erasca's R&D Expenses for the twelve months ending Jun 30, 2026 was $108.88M, up 7.9% year over year. For fiscal 2025 it was $92.85M, down 19.5% from the year before. The highest annual figure on record is $115.36M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$92.85M-19.5%
FY2024Dec 31, 2024$115.36M+11.1%
FY2023Dec 31, 2023$103.82M-7.7%
FY2022Dec 31, 2022$112.46M+52.1%
FY2021Dec 31, 2021$73.92M+150.2%
FY2020Dec 31, 2020$29.55M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$35.90M+69.6%
Q1 FY2026Mar 31, 2026$27.27M+5.0%
Q4 FY2025Dec 31, 2025$23.24M-11.0%
Q3 FY2025Sep 30, 2025$22.47M-18.7%
Q2 FY2025Jun 30, 2025$21.17M-35.9%
Q1 FY2025Mar 31, 2025$25.97M-9.1%
Q4 FY2024Dec 31, 2024$26.12M+5.3%
Q3 FY2024Sep 30, 2024$27.63M+9.6%
Q2 FY2024Jun 30, 2024$33.03M+26.0%
Q1 FY2024Mar 31, 2024$28.57M+3.6%
Q4 FY2023Dec 31, 2023$24.81M-15.5%
Q3 FY2023Sep 30, 2023$25.21M-10.5%
Q2 FY2023Jun 30, 2023$26.22M-4.6%
Q1 FY2023Mar 31, 2023$27.59M+0.6%
Q4 FY2022Dec 31, 2022$29.36M+21.7%
Q3 FY2022Sep 30, 2022$28.18M+41.3%
Q2 FY2022Jun 30, 2022$27.49M+56.2%
Q1 FY2022Mar 31, 2022$27.43M+124.0%
Q4 FY2021Dec 31, 2021$24.13M+139.7%
Q3 FY2021Sep 30, 2021$19.95M+120.0%
Q2 FY2021Jun 30, 2021$17.60M+200.2%
Q1 FY2021Mar 31, 2021$12.25M–
Q4 FY2020Dec 31, 2020$10.07M–
Q3 FY2020Sep 30, 2020$9.07M–
Q2 FY2020Jun 30, 2020$5.86M–

More Erasca figures

See a number that looks wrong?